Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association

Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.

[1]  C. Kaczorowski,et al.  Pursuit of precision medicine: Systems biology approaches in Alzheimer’s disease mouse models , 2021, Neurobiology of Disease.

[2]  K. Blennow,et al.  Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease , 2021, JAMA neurology.

[3]  P. Tariot,et al.  Trial of Pimavanserin in Dementia-Related Psychosis. , 2021, The New England journal of medicine.

[4]  J. Luchsinger,et al.  Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. , 2021, The lancet. Diabetes & endocrinology.

[5]  A. Atri,et al.  Aducanumab produced a clinically meaningful benefit in association with amyloid lowering , 2021, Alzheimer's Research & Therapy.

[6]  Garam Lee,et al.  Alzheimer's disease drug development pipeline: 2021 , 2021, Alzheimer's & dementia.

[7]  R. Bateman,et al.  CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease. , 2020, Brain : a journal of neurology.

[8]  Y. Jeong,et al.  Genetic variants beyond amyloid and tau associated with cognitive decline , 2020, Neurology.

[9]  R. Bateman,et al.  Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease , 2020, The Journal of experimental medicine.

[10]  L. Tan,et al.  Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies , 2019, Ageing Research Reviews.

[11]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[12]  C. Iadecola,et al.  Neurovascular and Cognitive Dysfunction in Hypertension. , 2019, Circulation research.

[13]  B. Zinman,et al.  HbA1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy , 2018, Diabetes care.

[14]  J. Jost,et al.  Executive Summary , 1998, OECD Reviews of Pension Systems: Peru.

[15]  M. Dichgans,et al.  Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke , 2018, Neurology.

[16]  G. Biessels,et al.  Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications , 2018, Nature Reviews Endocrinology.

[17]  Quincy M. Samus,et al.  Dementia prevention, intervention, and care , 2017, The Lancet.

[18]  J. Götz,et al.  Tau-based therapies in neurodegeneration: opportunities and challenges , 2017, Nature Reviews Drug Discovery.

[19]  R. Schmidt,et al.  Remote changes after ischaemic infarcts: a distant target for therapy? , 2017, Brain : a journal of neurology.

[20]  V. Mok,et al.  Delayed-onset dementia after stroke or transient ischemic attack , 2016, Alzheimer's & Dementia.

[21]  M. Dichgans,et al.  Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment , 2016, Stroke.

[22]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[23]  R. Righart,et al.  Acute infarcts cause focal thinning in remote cortex via degeneration of connecting fiber tracts , 2015, Neurology.

[24]  L. Kappelle,et al.  Cognitive function in patients with diabetes mellitus: guidance for daily care , 2015, The Lancet Neurology.

[25]  Reinhold Schmidt,et al.  Strategic white matter tracts for processing speed deficits in age-related small vessel disease , 2014, Neurology.

[26]  M. Dichgans,et al.  Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. , 2011, Brain : a journal of neurology.

[27]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[28]  P. Scheltens,et al.  Risk of dementia in diabetes mellitus: a systematic review , 2006, The Lancet Neurology.